CN1503671A - 用于眼部炎病局部眼科治疗的药剂 - Google Patents

用于眼部炎病局部眼科治疗的药剂 Download PDF

Info

Publication number
CN1503671A
CN1503671A CNA028082001A CN02808200A CN1503671A CN 1503671 A CN1503671 A CN 1503671A CN A028082001 A CNA028082001 A CN A028082001A CN 02808200 A CN02808200 A CN 02808200A CN 1503671 A CN1503671 A CN 1503671A
Authority
CN
China
Prior art keywords
group
hydrogen atom
treatment
ocular
eye
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028082001A
Other languages
English (en)
Chinese (zh)
Inventor
��Ұ¡˾
上野隆司
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sucampo GmbH
Original Assignee
Sucampo GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sucampo GmbH filed Critical Sucampo GmbH
Publication of CN1503671A publication Critical patent/CN1503671A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CNA028082001A 2001-04-12 2002-04-12 用于眼部炎病局部眼科治疗的药剂 Pending CN1503671A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28316901P 2001-04-12 2001-04-12
US60/283,169 2001-04-12

Publications (1)

Publication Number Publication Date
CN1503671A true CN1503671A (zh) 2004-06-09

Family

ID=23084835

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA028082001A Pending CN1503671A (zh) 2001-04-12 2002-04-12 用于眼部炎病局部眼科治疗的药剂

Country Status (12)

Country Link
US (1) US20020187998A1 (enExample)
EP (1) EP1379247A1 (enExample)
JP (1) JP2004529928A (enExample)
KR (1) KR20040007494A (enExample)
CN (1) CN1503671A (enExample)
AR (1) AR033151A1 (enExample)
BR (1) BR0208939A (enExample)
CA (1) CA2445508A1 (enExample)
MX (1) MXPA03009273A (enExample)
NO (1) NO20034560L (enExample)
NZ (1) NZ529255A (enExample)
WO (1) WO2002085359A1 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1406700A1 (en) 2001-07-06 2004-04-14 Sucampo AG Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
RU2004118424A (ru) * 2001-11-19 2005-05-10 Новартис АГ (CH) Применение аскомицина для лечения блефарита
BR0313425A (pt) * 2002-08-09 2005-07-05 Sucampo Pharmaceuticals Inc Composição oftálmica para tratamento de alergia ocular, uso do composto de macrolìdeo e pacote comercial
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
AR042890A1 (es) * 2003-01-16 2005-07-06 Sucampo Pharmaceuticals Inc Metodo de tratamiento del ojo seco con una composicion oftalmica que contiene un compuesto macrolido
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
JP2007505932A (ja) 2003-09-18 2007-03-15 マクサイト， インコーポレイテッド 経強膜送達
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
CA2597590A1 (en) 2005-02-09 2006-08-17 Macusight, Inc. Formulations for ocular treatment
KR101478164B1 (ko) 2006-02-09 2014-12-31 산텐 세이야꾸 가부시키가이샤 안정한 제제와 그 제조 및 사용 방법
AU2007230964B2 (en) * 2006-03-23 2012-07-19 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
US8536190B2 (en) * 2007-01-30 2013-09-17 Allergan, Inc. Treating unwanted ocular conditions using an ascomycin macrolactam
WO2015188126A1 (en) * 2014-06-06 2015-12-10 The Schepens Eye Research Institute, Inc. Compositions and methods for treating tumors and immune based inflammatory diseases
HUE048564T2 (hu) * 2015-01-26 2020-08-28 Bausch & Lomb Szemészeti szuszpenzió készítmény
KR101710412B1 (ko) 2015-09-15 2017-02-27 인제대학교 산학협력단 Ycg063을 유효성분으로 함유하는 염증성 안구질환 예방 또는 치료용 약학조성물

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894366A (en) * 1984-12-03 1990-01-16 Fujisawa Pharmaceutical Company, Ltd. Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same
ZA905202B (en) * 1989-07-05 1991-04-24 Fujisawa Pharmaceutical Co Aqueous liquid composition for external use
ATE126803T1 (de) * 1989-11-09 1995-09-15 Sandoz Ag Heteroatome enthaltende tricyclische verbindungen.
CA2054983A1 (en) * 1990-11-08 1992-05-09 Sotoo Asakura Suspendible composition and process for preparing the same
ES2154262T3 (es) * 1991-04-26 2001-04-01 Fujisawa Pharmaceutical Co Uso de compuestos macrolidos para enfermedades oculares.
AR004480A1 (es) * 1995-04-06 1998-12-16 Amico Derin C D Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen

Also Published As

Publication number Publication date
EP1379247A1 (en) 2004-01-14
JP2004529928A (ja) 2004-09-30
BR0208939A (pt) 2004-04-20
WO2002085359A1 (en) 2002-10-31
MXPA03009273A (es) 2004-02-12
NZ529255A (en) 2006-09-29
NO20034560L (no) 2003-12-09
CA2445508A1 (en) 2002-10-31
US20020187998A1 (en) 2002-12-12
KR20040007494A (ko) 2004-01-24
AR033151A1 (es) 2003-12-03
NO20034560D0 (no) 2003-10-10

Similar Documents

Publication Publication Date Title
CN1259049C (zh) 包含白介素－2抑制剂和抗菌剂的局部给药组合物
CN1190194C (zh) 用于治疗干眼的大环内酯化合物的应用
CN1074932C (zh) 眼用组合物
CN1108152C (zh) 口服雷怕霉素配方
KR20040007494A (ko) 염증성 눈 질환의 국소용 눈 치료제
JP2011012071A (ja) アレルギー性疾患を処置する為のｆｋ５０６誘導体を含む医薬組成物及びその使用
CN1297270C (zh) 包含子囊霉素的眼用组合物
TW201825091A (zh) 西羅莫司或其藥學上可容許的鹽之用途
CN1224420C (zh) 视细胞功能紊乱治疗剂
US20040198763A1 (en) Method of treating dry eye with a macrolide compound
CN1133424C (zh) 口服给药的雷怕霉素制剂
CN1133429C (zh) 大环内酯化合物用于治疗成人呼吸窘迫综合症的用途
US20050070468A1 (en) Use of fk506 and analogues for treating allergic diseases
CN1674868A (zh) 包含药物、软膏基质和增溶剂/分散剂的眼用软膏剂组合物
CN1342075A (zh) 脂质体制剂
KR20050071491A (ko) 천식의 치료를 위한 베타2-작용제와 배합된 타크롤리무스 (ｆｋ506) 유도체의 용도
AU2002248014A1 (en) Agent for topical ophthalmic treatment of ocular inflammatory diseases
AU2002314558A1 (en) Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
HK1070282A (en) Pharmaceutical composition comprising a tricyclic compound for the prevention or treatment of skin diseases
HK1036406B (en) Use of macrolide compounds for the treatment of ards

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication